Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12738MR)

This product GTTS-WQ12738MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12738MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14765MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ10608MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ1468MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ8308MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HM-12525A
GTTS-WQ9725MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ800MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ5181MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ13400MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PR-1594804
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW